Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis April 21, 2026 mental-health ONLY AVAILABLE IN PAID PLANS. Originally reported by biospace. Read more Source: https://www.biospace.com/press-releases/eupraxia-pharmaceuticals-reports-positive-nine-month-tissue-health-and-symptom-data-from-the-highest-dose-cohort-in-its-ongoing-phase-1b-2a-resolve-trial-in-eosinophilic-esophagitis
